Dear Reader, Over the past eight years, Human Vaccines & Immunotherapeutics (HV&I) has become a serious and valuable publication forum in the field of vaccinology and immunotherapy. In addition to the latest research, a variety of special features, like Reviews, Commentaries and News, have found a home in HV&I. Last year, we also started to publish Meeting Special Issues.
We are very pleased to present the current Special Issue on DNA Vaccines, which is based on the recent DNA Vaccines 2011 conference. Dr David Weiner (Program Chairman) and Dr Kenneth Ugen have kindly served as Guest-Editors for this Special issue, and have assembled an excellent selection of peer-reviewed papers related to DNA vaccines. Selected speakers of the 2011 meeting were invited to contribute to this Special Issue by submitting their latest research or providing reviews on various aspects of DNA vaccination and immunotherapy. Please read the Introduction by Drs Weiner (Editorial Board) and Ugen (Associate Editor) that overviews the range of topics covered in this Special Issue (page 1554).
As usual, the current issue features a selection of the latest news in our News, Policy & Profiles (NP&P) section. This monthly track also features company profiles and critical opinion pieces on timely developments in the field of vaccines and immunotherapeutics. Please contact the Acquisitions Editor Eva Riedmann (eva@landesbioscience.com), if you wish to contribute to our NP&P section in the future.
Finally, we want to remind you that HV&I has recently lowered its open access (OA) fees significantly. The cost to make an original research paper OA is $750. For all other types of papers, the OA fee is $500. With this step we want to acknowledge that many scientists wish for free access to and distribution of published articles.
Enjoy the benefits of several popular website features offered by HV&I: Subscribe to our RSS feed to see the latest published papers and "Like" us on Facebook for daily updates. With our iPad application you can read the full issue of HV&I anywhere, just as you would the print issue. 
